» Articles » PMID: 15885069

Does Drug Abuse Alter Microglial Phenotype and Cell Turnover in the Context of Advancing HIV Infection?

Overview
Specialty Neurology
Date 2005 May 12
PMID 15885069
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to test the effects of drug abuse, in particular opiate abuse, on the phenotype and turnover of microglial cells within the brain in the context of advancing HIV infection. Basal ganglia and hippocampus sections were studied in 51 cases divided into six groups: HIV-negative normal controls, HIV-negative drug abusers, AIDS nondrug abusers, AIDS drug abusers, HIV encephalitis (HIVE) nondrug abusers and HIVE drug abusers. None of the cases studied had received highly active anti-retroviral therapy (HAART). Microglial phenotypes were defined using CD14, CD16, CD68 and major histocompatibility class II (MHC II). Microglial turnover was assessed using terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (TUNEL) (DNA damage), BAX (proapoptotic marker), Fas (CD95) (proapoptotic), proliferating cell nuclear antigen (PCNA) (proliferation and DNA repair), Ki-67 (cell proliferation) and BCL-2 (antiapoptosis). We find increased expression of MHC II and CD16 in response to drug abuse. We also noted increased levels of TUNEL positivity in drug abusers compared to nondrug abusers, although conversely we found lower levels of BAX in those who had abused drugs. We find no evidence of microglial proliferation in any of our study groups, including HIVE, although HIV infection leads to increased expression of CD16, CD68 and MHC II. CD14 expression was restricted to perivascular microglia in all groups (including normal controls) apart from the two HIVE groups where some but not all cases also showed parenchymal expression of CD14. In contrast, CD16 was found in parenchymal microglia in all groups. Using high-pressure antigen retrieval and tyramide signal amplification, we find moderately high levels of CD16 expression in the parenchyma of normal brains which is not normally observed using standard avidin/biotin complex (ABC) techniques. This suggests that a low basal expression of CD16 occurs in many resident microglial cells which may potentially be upregulated in HIV-infected individuals. From these data, we suggest that not all the CD16+ parenchymal cells detected in AIDS brains (using ABC) represent influx of monocyte lineage cells from the blood. Finally the increased expression of MHC II and CD68 detected in drug abusers with HIVE compared to nondrug abusers with HIVE suggests that the combination of drug abuse and HIV infection has a greater deleterious effect on the brain than either individual insult on its own.

Citing Articles

Depressive-like Behavior Is Accompanied by Prefrontal Cortical Innate Immune Fatigue and Dendritic Spine Losses after HIV-1 Tat and Morphine Exposure.

Nass S, Hahn Y, Ohene-Nyako M, McLane V, Damaj M, Thacker 2nd L Viruses. 2023; 15(3.

PMID: 36992299 PMC: 10052300. DOI: 10.3390/v15030590.


Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis.

Xie M, Su C Front Oncol. 2023; 12:1006284.

PMID: 36761422 PMC: 9902941. DOI: 10.3389/fonc.2022.1006284.


Independent actions by HIV-1 Tat and morphine to increase recruitment of monocyte-derived macrophages into the brain in a region-specific manner.

Leibrand C, Paris J, Jones A, Ohene-Nyako M, Rademeyer K, Nass S Neurosci Lett. 2022; 788:136852.

PMID: 36028004 PMC: 9845733. DOI: 10.1016/j.neulet.2022.136852.


Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?.

Contoreggi C, Chrousos G, Di Mascio M Neurobehav HIV Med. 2021; 7:53-75.

PMID: 34295195 PMC: 8293862. DOI: 10.2147/nbhiv.s86309.


HIV-1 Tat and morphine decrease murine inter-male social interactions and associated oxytocin levels in the prefrontal cortex, amygdala, and hypothalamic paraventricular nucleus.

Nass S, Lark A, Hahn Y, McLane V, Ihrig T, Contois L Horm Behav. 2021; 133:105008.

PMID: 34171549 PMC: 8277758. DOI: 10.1016/j.yhbeh.2021.105008.